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Purpose: To investigate and test the feasibility of adaptive 3D image based BT planning for cervix cancer
patients in settings with limited access to MRI, using a combination of MRI for the ﬁrst BT fraction and
planning of subsequent fractions on CT.
Material and methods: For 20 patients treated with EBRT and HDR BT with tandem/ring applicators two
sets of treatment plans were compared. Scenario one is based on the ‘‘gold standard’’ with individual
MRI-based treatment plans (applicator reconstruction, target contouring and dose optimization) for
two BT applications with two fractions each. Scenario two is based on one initial MRI acquisition with
an applicator in place for the planning of the two fractions of the ﬁrst BT application and reuse of the tar-
get contour delineated on MRI for subsequent planning of the second application on CT. Transfer of the
target from MRI of the ﬁrst application to the CT of the second one was accomplished by use of an auto-
matic applicator-based image registration procedure. Individual dose optimization of the second BT
application was based on the transferred MRI target volume and OAR structures delineated on CT.
Material and methods: DVH parameters were calculated for transferred target structures (virtual dose
from MRI/CT plan) and CT-based OAR.
Material and methods: The quality of the MRI/CT combination method was investigated by evaluating
the CT-based dose distributions on MRI-based target and OAR contours of the same application (real dose
from MRI/CT plan).
Results: The mean difference between the MRI based target volumes (HR CTVMRI2) and the structures
transferred from MRI to CT (HR CTVCT2) was 1.7 ± 6.6 cm3 (2.9 ± 20.4%) with a median of 0.7 cm3.
Results: The mean difference between the virtual and the real total D90, based on the MRI/CT combina-
tion technique was1.5 ± 4.3 Gy EQD2. This indicates a small systematic underestimation of the real D90.
Conclusions: A combination of MRI for ﬁrst fraction and subsequent CT based planning is feasible and easy
when automatic applicator-based image registration and target transfer are technically available. The
results show striking similarity to fully MRI-based planning in cases of small tumours and intracavitary
applications, both in terms of HR CTV coverage and respecting of OAR dose limits. For larger tumours
and complex applications, as well as situations with unfavourable OAR topography, especially for the sig-
moid, MRI based adaptive BT planning remains the superior method.
 2012 Elsevier Ireland Ltd. Radiotherapy and Oncology 107 (2013)Open access under CC BY-NC-ND license. 
75–81Magnetic resonance imaging (MRI) based brachytherapy (BT)
allows appropriate delineation of target volumes for brachyther-
apy treatment planning [1,2]. Several studies could provide de-
tailed dosimetric data for target and organs at risk (OAR) [3–9].
The deﬁnition of the High Risk Clinical Target Volume (HR CTV)
is often used as the major basis for treatment planning. Proper dose
shaping, i.e., escalating the dose for MRI based target volumes
while keeping it reasonably low for OAR, seems to be the majorol and minimizing late
adiotherapy, Comprehensive
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 CC BY-NC-ND license. side effects [9,10]. However, the use of an MRI for each individual
brachytherapy fraction with the applicator in place is in many
countries and centres difﬁcult to organize and is expensive. There
is evidence that the use of computed tomography (CT) only for
brachytherapy target volume deﬁnition is inferior to MRI and
introduces major uncertainties in dose assessment and therefore
optimal dose planning [11]. The relevant question is, if there are
methods, which achieve a good compromise between the full
MRI approach with individual MRI for each fraction and the use
of CT only. An achievable solution might be the use of at least
one MRI for the ﬁrst fraction and the use of CT for subsequent frac-
tions or implantations, respectively. This paper applies a clinically
feasible method to combine the MRI based target volume contour
obtained for the ﬁrst fraction with CT datasets of subsequent
76 IGBT for cervix cancer: MRI-/CT- planning with MRI at ﬁrst fractionfractions, using an automatic, applicator-based co-registration
technique. The method is based on the following hypotheses,
which are tested within a retrospective treatment planning study.
The MRI based HR CTV contour for the ﬁrst fraction can be used
as an appropriate surrogate for the HR CTV to be used when subse-
quent fractions are scanned with CT for treatment planning.
The applicator and the HR CTV are linked together in a repro-
ducible way. This implies that after re-insertion of an identical tan-
dem/ring applicator the geometrical relation between HR CTV and
applicator will be the same.
The basis for the method introduced here is the use of an appli-
cator-based automatic registration between MRI and CT datasets
with a tandem/ring applicator in place. By now most planning sys-
tems can only perform applicator based fusion by manual place-
ment of landmarks on the applicator. An automatic procedure,
based on the known outer surface of the applicator seems to be
clinically feasible and practical. Followed by transfer of the MRI-
based contour to the CT dataset and OAR contouring directly on
CT, a fully contoured 3D dataset for further adaptive treatment
planning is achieved.
This hypothesis is tested by simulating its use and comparing
the dosimetric results against the gold standard, which is deﬁned
as an individual MRI for each single implantation/fraction.
Material and methods
Patients and application
Our standard treatment schedule consists of four high dose rate
(HDR) BT fractions which are given in two applications in consecu-
tive weeks [9,12]. For each fraction a D90P 7 Gy is prescribed to
the HR CTV, which corresponds to a total treatment D90P 85 Gy
in EQD2 (a/b = 10 Gy), including EBRT. The ﬁrst 20 patients meeting
the following inclusion criteria were selected for this study: (i) use
of the same applicator dimensions for both applications and (ii) two
MRI and one CT available for each application. The distribution of
FIGO stage classiﬁcation for local tumour stage was IB1 = 1,
IB2 = 1, IIB = 15, and IIIB = 3. The distribution of MRI-based HR
CTV volumes at the time of the ﬁrst BT treatment was 10–20 cm3
(3), 20–40 cm3 (12), 40–60 cm3 (2), and 60–90 cm3 (3). All patients
received 35–45 Gy external beam radiotherapy (EBRT) to the whole
pelvis, prior to the ﬁrst BT fraction. Except for one patient who re-
ceived 6 HDR BT fractions with a D90P 5 Gy prescribed to the
HR CTV, all patients were treated to our clinical standard. For the
ﬁrst fraction of each application an MRI-based treatment plan
was generated. On the second day of each application another
MRI series was acquired to verify positions of applicator and organs
at risk. If the organ motion between ﬁrst and second fractions were
not expected to lead to a substantial difference to the planning aims
for dose parameters, the plan from the ﬁrst fraction was reused for
treatment of the second fraction without any further optimization.
For small tumours the MRI/CT compatible Vienna intracavitary
tandem/ring applicators (Nucletron, Veenendaal, The Netherlands)
with intrauterine length of 40 or 60 mm and diameters of 26, 30
and 34 mm were used. For larger tumours with parametrial exten-
sions that could not be covered with the intracavitary applicators
alone, or for situations with difﬁcult OAR topography, additional
interstitial needles, parallel to the tandem, were used in the ring
[13,14]. For two cases with more locally advanced disease (VHR
CTV > 60 cm3) a custom made applicator with additional interstitial
needles deviating from the tandem axis was used (ViennaII) [15].Imaging and contouring
All patients underwent MR imaging with a 0.2 Tesla low-ﬁeld
system (Siemens Magnetom Open-Viva; Siemens AG, Erlangen,Germany) at the time of BT, with applicators in place. The details
about the sequences used are given in Dimopoulos et al. [16]. In
addition to the MRI all patients underwent CT imaging (Siemens
Somatom Plus 4 Volume Zoom, Erlangen, Germany). The average
time between the start of MRI and CT acquisition was 54 min.
While for all MR images the slice thickness was 5 mm, CT scans
were taken with 4 mm slice thickness for 11 patients and 2 mm for
9 patients. The use of intravenous contrast was not performed sys-
tematically in this cohort of patients. OAR was contoured on the CT
images by physicians without knowledge of the corresponding MRI
or with at least one month time difference after they contoured on
MRI.Applicator reconstruction
Applicator surface reconstruction on MR and CT images was
performed using the 3D applicator library implemented in the
treatment planning system (TPS) Oncentra GYN (Nucletron, Vee-
nendaal, v. 1.2.1.–1.2.3). By deﬁning the tip of the tandem and
the centre of the ring, the model was placed on the 3D MRI dataset.
Fine tuning was done manually by shifting and rotating the whole
applicator. In the ring part of the applicator holes for the interstitial
needles could be used as additional markers to deﬁne the correct
applicator rotation on MRI, as they produce high intensity signals
on the MRI due to their ﬁlling with blood or other ﬂuids. For accu-
rate representation of the actual source path in the ring, we imple-
mented a modiﬁed circular source path in the treatment planning
software, which ﬁts best for the dwell positions which are most
relevant for our clinical standard loading pattern [17]. Veriﬁcation
of this source path with autoradiographs is included in our clinical
applicator and TPS commissioning procedures.
For reconstruction based on CT images the visible source chan-
nel as well as the needle guiding holes could be matched with the
contours of the library applicator. MRI- or CT-based reconstruction
of the interstitial needles was done by selecting the position of the
guiding hole built into the applicator model and marking the cor-
responding position of the needle tip on the image. Small manual
adjustments had to be made in case a needle was bent, so its
source path clearly deviated from a straight line.Target transfer between MRI and CT
For the fully MRI-based plans of the ﬁrst and second BT applica-
tion targets (HR CTV, GTV) and OAR (bladder, rectum, and sigmoid)
contours delineated on MRI were used for dose planning according
to our clinical protocol [9,12,18,19].
For the CT-based plans of the second applications of each treat-
ment series, organs at risk were delineated on the CT images. How-
ever the target contours were copied from the MRI of the ﬁrst
application (MRI1) to the corresponding CT of the second applica-
tion (CT2). To copy the targets a rigid image fusion option in the
TPS was used. As a ﬁrst step, applicators were reconstructed on
both the MRI and the CT. The internal applicator coordinate sys-
tems were then used as a reference for automatic rigid image reg-
istration between the MRI and CT series. After the registration, the
target structures delineated on the MRI (HR CTVMRI1) were loaded
and stored onto the CT dataset, keeping their position relative to
the applicator ﬁxed. In case of overlaps with OAR contours de-
picted on CT images the transferred target contours were adjusted.
In the rest of this work, these transferred targets will be referred to
as HR CTVCT2.
In order to estimate the inﬂuence of the image resolution on the
quality of the target transfer procedure, two subgroups of images
with CT slice thickness of 4 mm (n = 11) and 2 mm (n = 9) were
evaluated separately.
Table 1
Schematic workﬂow of the MRI/CT combination method.
1st Application (MRI) 2nd Application (CT)
3D applicator reconstruction 3D applicator reconstruction
Target delineation Target transfer from 1st MRI via image fusion based on applicator
OAR delineation OAR delineation
Dose planning and optimization Dose planning and optimization
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For each patient, an MRI of the ﬁrst and second applications
(MRI1, MRI2) and a CT of the second application (CT2) were in-
cluded in this study. All treatment plans were computed with
the Oncentra GYN TPS. Manual dwell time optimization was per-
formed, taking into account the protocol based dose constraints
[9]. DVH parameters were reported for target structures (HR
CTV) and OAR (bladder, rectum, sigmoid) [2].
CT-based dose optimization was performed by a physicist with-
out knowledge of the images, target and organ contours, and dose
distribution or DVH parameters of the MRI-based plan of the sec-
ond application.
An overview of the whole planning workﬂow used in this study
is given in Table 1.Dose summation and plan evaluation
In total 60 treatment plans for 20 patients were investigated.
The volumes and D90 of the HR CTV as well as the D2cc of organs
at risk (bladder, rectum, sigmoid) were included in the detailed
comparison of the MRI and MRI/CT techniques.
For each patient two sets of BT plans were used to compute the
normalized biological equivalent dose of the total treatment con-
sisting of EBRT + four fractions of BT, i.e., (i) two fully MRI based
plans and (ii) one MRI-based and one combined MRI/CT-based
plan. For each BT application of two fractions, one optimized plan
was computed for the ﬁrst fraction. The same plans and dose val-
ues were used for the second fractions. The total treatment doses
were calculated in EQD2 using a/b = 10 Gy for target and a/
b = 3 Gy for OAR.
For the fully MRI-based treatment scenario the dose of EBRT
(45–50 Gy physical dose) was added to the doses from the set of
twoMRI-based treatment plans for the two BT applications. The re-
sult of this calculation will subsequently be referred to as ‘‘MRI-
plan dose’’.
For the MRI/CT-based scenario, the total dose was calculated
from EBRT plus the dose from the MRI-based plan of the ﬁrst appli-
cation and the dose from the CT-based plan of the second applica-
tion. The result represents the DVH values which would be
reported without any knowledge of an MRI at the time of the sec-
ond application. This is the dose we would expect to be delivered
to the patient using MRI for the ﬁrst and CT for subsequent appli-
cations. Hence, further on, this dose will be referred to as ‘‘virtual
dose for MRI/CT-plan’’.
For assessing the quality of the combined MRI/CT planning
method, the CT-based dose distributions were also evaluated on
the original MRI images and corresponding contours of the second
application. The loading pattern and dwell times were transferred
from the CT to the MRI dataset and DVH parameters were com-
puted for the MRI-based target and OAR contours. The result gives
the dose that would have really been delivered to the MRI-based
target volume of the second BT by application of the CT plan, and
is therefore referred to as ‘‘real dose for MRI/CT-plan’’.
The three types of dose summation are illustrated by a sche-
matic drawing in Fig. 1.
Differences between DVH parameters based on different plan-
ning scenarios were calculated and reported as mean difference±1 standard deviation. The observed differences were evaluated
using a two-sided paired t-test. Differences with p < 0.05 were con-
sidered to be statistically signiﬁcant.
Results
Target volumes
The mean difference between volumes of target contours delin-
eated on the MRI of the ﬁrst and second applications, i.e., volume of
HR CTVMRI1  volume of HR CTVMRI2, which can be inﬂuenced by
tumour shrinkage between fractions, varying image quality and
contouring uncertainties, was 4.6 ± 7.4 cm3 (9.2 ± 17.9%) with a
median of 3.1 cm3. According to a two-sided t-test this difference
was statistically signiﬁcant (p = 0.009). The volumes of HR CTVMRI2
structures exceeded the volumes of the structures transferred from
MRI to CT (HR CTVCT2) by 1.7 ± 6.6 cm3 (2.9 ± 20.4%) with a median
of 0.7 cm3 (p = 0.26).
The ﬁrst MRI target volumes (HR CTVMRI1) were found to be
slightly larger than the volumes of the same structures transferred
onto the CT dataset (HR CTVCT2) by 3.1 ± 3.9 cm3 (9.7 ± 9.5%) with a
median of 2.5 cm3 (p = 0.002). Volume was lost due to interpola-
tion techniques when copying the contours between two image
series. For two cases the volume of the original HR CTVMRI1 ex-
ceeded the volume of the transferred structure, calculated on the
CT images, by more than 20%. For plans based on CT datasets with
4 mm slice thickness the mean transfer-related volume decrease
was 15.4 ± 9.4% (p = 0.08), and for those with 2 mm slice thickness
2.7 ± 1.7% (p = 0.04).Comparison of physical dose per fraction
For the fully MRI based plans the mean D90MRIplan of the HR
CTVMRI2 volumes was 7.9 ± 0.7 Gy. The average of the virtual
D90CTplan was 7.7 ± 0.8 Gy for HR CTVCT2. When the CT-based plans
were evaluated on the purely MRI-based contours, HR CTVMRI2, the
mean real D90CTplan was 8.0 ± 1.2 Gy. The comparison of virtual
and real doses from the CT plans is shown in Fig. 2.
The mean difference between the real and virtual D90CTplan, i.e.,
D90CTplan HR CTVMRI2  D90CTplan HR CTVCT2, was 0.28 ± 0.76 Gy
(0.54 ± 10.91%) for these fractions (p = 0.22). A positive value
means that the real D90 of the CT plan was higher when evaluated
on MRI structures.
For CT-based plans the DVH analysis for OAR delineated on the
CT images yielded a D2cc of 5.1 ± 0.8 Gy, 3.2 ± 0.8 Gy and
3.9 ± 0.7 Gy for bladder, rectum and sigmoid, respectively. Calcula-
tion of the D2cc of the CT-based plans on organ contours delineated
on MRI of the second application resulted in 5.0 ± 1.0 Gy,
2.9 ± 0.6 Gy and 3.5 ± 1.2 Gy for bladder, rectum and sigmoid.
Differences larger than ± 1 Gy between D2cc calculated on CT
and MRI organ contours were observed in 6 cases for bladder, in
1 case for rectum and in 5 cases for sigmoid.Comparison of total treatment dose
For comparison of the total treatment dose delivered with the
fully MRI-based and MRI/CT-combination techniques, the dose
from EBRT (45–50 Gy) was added to the corresponding doses for
Fig. 1. Schematic representation of the dose summation types for the two different treatment planning scenarios: (I) fully MRI-based planning (MRI plan dose), (II) combined
MRI/CT-based planning with (IIa) calculation of expected DVH values based on MRI of ﬁrst and CT of second application (MRI/CT plan – virtual dose) and (IIb) calculation of
dose that would be delivered to MRI-based target contours for both applications (MRI/CT plan – real dose).
Fig. 2. Comparison of D90 HR CTV in physical dose for one fraction, computed with
the CT-based plan for the MRI target contour (HR CTVMRI2) of the second application
and for the transferred target (HR CTVCT2) (real dose MRI/CT plan vs. virtual dose
MRI/CT plan). Open symbols correspond to intracavitary implants, ﬁlled symbols to
intracavitary + interstitial applications.
Fig. 3. Comparison of D90 for the whole course of treatment for the fully MRI-based
BT (D90MRI) and the MRI/CT method (D90MRI/CT). Doses were calculated with
corresponding plans on the same MRI-based HR CTV contours (real dose MRI/CT
plan vs. dose MRI plan). Different symbols indicate the range of HR CTVMRI volumes.
Open symbols correspond to intracavitary implants, ﬁlled symbols to intracavi-
tary + interstitial applications.
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doses are reported for target and OAR in Table 2.
The virtual D90 of the MRI/CT-based plans was found to be
1.5 ± 4.3 Gy lower than the corresponding total real D90
(p = 0.14). The mean difference of D90 HR CTV for the fully MRI-
based plans and the real D90 HR CTV for the MRI/CT-combination
technique was 0.7 ± 5.3 Gy. A negative sign means that on aver-
age the real D90 was lower for the fully MRI based plans than for
the MRI/CT plans. The difference was not found to be statistically
signiﬁcant (p = 0.59).
For OAR, calculation of the DVH for the MRI/CT plans on CT- or
MRI-based structures resulted in mean differences of D2cc of
0 ± 4.9 Gy, 1.3 ± 1.2 Gy and 1.1 ± 4.2 Gy, for bladder (p = 0.99),
rectum (p = 0.0001) and sigmoid (p = 0.26), respectively. A positivevalue means the virtual total D2cc was larger than the real total
D2cc. When MRI and MRI/CT plans both were evaluated with the
MRI anatomy, the mean differences of real total D2cc for MRI vs.
MRI/CT plans were 0 ± 3.6 Gy (bladder, p = 0.99), 0.1 ± 2.7 Gy (rec-
tum, p = 0.90) and 1.0 ± 2.9 Gy (sigmoid, p = 0.15). A positive value
means that the real total D2cc of the MRI/CT plans was larger than
the total D2cc of the MRI plan (Fig. 4).
The duration of the time between the start of the MRI and CT
acquisition was not found to correlate with the difference between
DVH parameters of the CT plans computed on CT vs. MRI contours.Discussion
MRI is nowadays considered the gold standard for 3D image
guided adaptive cervix cancer brachytherapy as it provides
Table 2
Summary of the DVH parameters used for optimization, for HR CTV and OAR. Total doses are given for the three scenarios: ‘‘MRI plan’’ (dose delivered to the patient with fully
MRI-based BT), ‘‘MRI/CT plan virtual dose’’ (expected dose computed from 1 MRI-based and 1 MRI/CT-based application) and ‘‘MRI/CT plan real dose’’ (dose that would have been
delivered with MRI/CT method; calculations based on MRI contours for both applications).
D90 (HR CTV) [Gy EQD2] D2cc bladder [Gy EQD2] D2cc rectum [Gy EQD2] D2cc sigmoid [Gy EQD2]
MRI-plan dose (2 MRI)
Mean 91.2 76.0 57.2 62.8
SD 5.3 8.7 5.9 7.2
MRI/CT plan virtual dose (1 MRI + 1 CT)
Mean 90.4 76.0 58.6 64.9
SD 5.0 8.1 4.8 6.2
MRI/CT plan real dose (2 MRI)
Mean 91.9 76.0 57.3 63.8
SD 6.4 8.8 4.1 8.0
Fig. 4. Comparison of D2cc for OAR, for the whole treatment course, calculated for
MRI anatomy. D2cc MRI denotes the fully MRI-based plan parameters, D2cc MRI/CT
corresponds to the plans generated with the MRI/CT combination method (real dose
MRI/CT plan vs. dose MRI plan).
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planning. Clincal outcome [1,5,8,9,20,21] and dose–effect relations
for MRI-based BT [10,19,22,23] have been reported for targets and
OAR by various groups. The limitations of delineating target struc-
tures on CT images have recently been investigated in comparison
with MRI-based reference structures [11,24,25].
Since MRI is not available for planning of each BT fraction in all
institutions where image guided cervix cancer BT is performed,
other studies combining MRI and CT for different fractions have
been reported in the literature.
Beriwal et al. [26] ﬁrst reported the use of MRI at the time of the
ﬁrst BT planning with applicator in place, followed by subsequent
CT-based fractions. The target structure delineated on the MRI of
the ﬁrst fraction was used as a guideline for contouring on CT for
subsequent fractions. Clinical results of this MRI/CT hybrid meth-
od, for intracavitary cervix BT, were presented but not compared
to conventional plans or fully MRI-based plans.
Wakatsuki et al. [27] and Kang et al. [28] used MRI acquired be-
fore the BT treatment, without applicator in situ, to improve con-
touring of the HR CTV on subsequent CT images at the time of
brachytherapy. This way dose plans could be optimized to a more
realistic target structure than could be contoured on CT alone, and
OAR as depicted on CT. A similar MRI/CT technique was used by
Fokdal et al. [29] for MRI-based BT pre-planning with a MUPIT
applicator in situ.
An MRI/CT hybrid technique using MRI for pre-BT planning with
tandem ovoid applicators in situ and subsequent plan adaptationbased on CT contours at the time of BT treatment was reported
by Dolezel et al. [30]. In their study rigid image fusion of MR and
CT images based on pre-deﬁned applicator points in combination
with soft-tissue landmarks was applied and contours were trans-
ferred fromMRI to CT for optimization of the pre-plan, on OAR con-
tours depicted on CT. The technique was evaluated by comparison
of fully 3D based hybrid MRI/CT plans with standard plans (HR CTV
D90 vs. dose to point A). The authors conﬁrmed substantial
improvement of target coverage and OAR sparing using an adap-
tive treatment strategy.
The technique of combining MRI for the ﬁrst BT fraction and CT
for subsequent adaptive planning of the following fractions, based
on automatic rigid image registration based on the tandem-ring
applicators, for systematic and reproducible transfer of the target
contours from MRI to CT plans, is reported here for the ﬁrst time.
In all other studies where combinations of MRI and CT for adaptive
planning of cervix cancer BT were analyzed, the results could not
be directly compared to a fully MRI-based comparison set of treat-
ment plans, as it is done in the present study. Moreover, our study
covers various types of target volumes occurring in clinical prac-
tice, which allows for comparison between purely intracavitary
implants and those including interstitial needles.
In four cases the difference of D90CTplan per fraction for HR
CTVCT2 and HR CTV MRI2 was larger than 1 Gy (Fig. 2). Three of these
outliers correspond to intermediate HR CTV volumes (25–29 cm3).
All of them were treated with additional interstitial needles due to
OAR topography. With small volumes and additional needles small
differences in the target structures can have large impacts on the
DVH as steep dose gradients occur close to the target surface.
The fourth outlier corresponds to the largest HR CTV volume in
the sample (86.6 cm3), which was treated with the Vienna II appli-
cator. An inspection of the MRI-based plans of the ﬁrst and second
applications for this patient revealed that the applicator position in
relation to the target was different for the two applications. The
applicator rotation in relation to the anterior-posterior axis as de-
ﬁned by the MRI was 21 while no rotation of the target structure
could be observed.
Hence, after the automatic transfer of HR CTVMRI1 to the CT of
the second application the CT plan was generated for an anatomi-
cal situation, which was signiﬁcantly different from the real anat-
omy as depicted on the MRI for that day. Therefore it was not
possible to achieve the desired target coverage when planning on
the CT, taking into account also the difﬁcult sigmoid topography.
The virtual D90 was smaller than 7 Gy. However, when projected
onto the MRI anatomy a D90 of 7.9 Gy was reached by the MRI/
CT-based plan.
As indicated in Fig. 2 the largest deviations of the D90 between
the two methods were found for combined intracavitary plus
interstitial implants. Considering the whole data sample, no clear
80 IGBT for cervix cancer: MRI-/CT- planning with MRI at ﬁrst fractioncorrelation was found between the D90 of the HR CTVCT2 or HR
CTVMRI2 and the tumour size or application technique.
The results of the analysis of total treatment dose differences
between the full MRI and MRI/CT combination methods (Fig. 3)
show that while planning with CT images the real D90 was under-
estimated on average by 1.5 ± 4.3 Gy. However, the mean differ-
ence between D90 of the fully MRI-based plans and MRI/CT plans
evaluated on the actual MRI anatomy was only 0.7 ± 5.3 Gy, with
the real D90 for MRI/CT plans being on average slightly larger than
for the MRI plans. The observed differences were not statistically
signiﬁcant. Therefore, on average, the quality of the MRI/CT combi-
nation method seems comparable to the fully MRI-based planning.
The main reason for the deviations found for individual plans are
the differences in volume and shape of the target contours be-
tween transferred target HR CTVCT2 and actual HR CTVMRI2 target.
These differences however are partly due to volume loss during
the transfer procedure (interpolation between MRI and CT slices
with different alignment and thickness) and actual tumour shrink-
age between consecutive treatment weeks. However, as these
cases received BT after or at the end of EBRT the tumour shrinkage
was less pronounced compared to our previous ﬁndings also based
on different treatment schedules [18]. The latter is reﬂected in the
differences of the MRI1 and MRI2 target contours. As half of the pa-
tients were imaged with 2 mm slice thickness for CT the depen-
dence of HR CTV volume loss on image resolution could be
studied. The measured tumour shrinkage was found to be of the
same order as the volume loss during target transfer, when using
4 mm slice thickness, i.e., 8.8 ± 20.5% and 15.4 ± 9.4%, respectively.
For 2 mm CT slices the average transfer-related volume loss was
reduced to 2.7%. However, for the two planning methods no corre-
lation between the differences in total D90 with CT slice thickness
could be detected in either of the two CT subgroups.
There was only one case where the minimum dose constraint
for the MRI-based HR CTV was missed by the MRI/CT plan. The
D90MRI/CT of the HR CTVMRI was 77.0 Gy. However, for this target,
which was the second largest in the sample (VHR CTV = 67.4 cm3)
the total D90 of the fully MRI-based plan was already only 81.9 Gy.
For one plan the real total D2cc MRI/CT for sigmoid failed to stay
below the dose limit by 2 Gy, even though there was no violation
encountered during ‘‘virtual dose’’ planning with the CT-based
structures. Depiction of the sigmoid in this patient’s CT scan was
not very clear, which introduced a higher uncertainty in the CT
contouring than for other cases. Moreover, non-negligible inter-
fraction variations, i.e., organ motion between MRI and CT acquisi-
tion, might have taken place and may have contributed to this
large deviation.
For all other cases all dose constraints for OAR were fulﬁlled.
Special information from clinical examination was not taken
into account while planning on CT. This limitation constitutes a
disadvantage of any retrospective treatment planning study.
Therefore, during a clinical implementation phase of this method
a parallel prospective protocol should be applied.
The present analysis is limited to tandem/ring applicators,
although further work should show appropriate use of the under-
lying method for other application techniques.Conclusions
This study has shown that a combination of MRI for ﬁrst frac-
tion and subsequent CT based planning is feasible as well as quick
and easy when automatic applicator-based image registration and
target transfer are implemented in the TPS. The results show
striking similarity to fully MRI-based planning in cases of small tu-
mours and intracavitary applications, both in terms of HR CTV cov-
erage and respecting of OAR dose limits. The MRI/CT combinationmethod may further be improved by focussing on information
from clinical examination in the CT-based planning process and
better understanding of CT contouring.
However, for larger tumours and complex applications, as well
as situations with unfavourable OAR topography, especially for the
sigmoid, MRI based adaptive BT planning remains the superior
method and is hence still to be considered as the gold standard.Conﬂict of interest statement
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